Biocon Overhauls Top Management as Biocon Biologics Integration Deepens

The latest update is out from Biocon Limited ( (IN:BIOCON) ).

Biocon’s board has approved a major reshaping of its top leadership as part of its ongoing integration with Biocon Biologics to create a unified global biopharmaceutical business. The company accepted the resignation of CEO and Managing Director Siddharth Mittal, who will move to another leadership role within the Biocon Group, and named Biocon Biologics chief Shreehas Pradeep Tambe as the new CEO and MD for a five-year term from April 1, 2026, subject to shareholder approval.

The board also endorsed the internal transfer of Biocon Biologics’ finance and governance leaders into Biocon, appointing Kedar Narayan Upadhye as Chief Financial Officer and designating Akhilesh Nand as a Key Managerial Personnel heading governance, risk and compliance. In a broader realignment of senior management, the company is bringing Biocon Biologics’ HR and technology heads into Biocon’s top team while several existing senior executives will cease to be designated senior management personnel from March 31, 2026, underscoring a deeper structural consolidation within the group.

More about Biocon Limited

Biocon Limited is an India-based biopharmaceutical company headquartered in Bengaluru, operating in the biotechnology and biologics segments. The group focuses on developing and manufacturing biosimilars, novel biologics, and active pharmaceutical ingredients for global markets, with a growing emphasis on building an integrated, unified biopharmaceutical platform through its subsidiary Biocon Biologics.

Average Trading Volume: 171,147

Technical Sentiment Signal: Buy

Current Market Cap: 614.9B INR

Learn more about BIOCON stock on TipRanks’ Stock Analysis page.